Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly and RNAi therapeutics specialist OliX ... benefits for patients and drive progress in metabolic health,” he added. Lilly’s once-weekly GIP/GLP-1 receptor agonist tirzepatide, which holds ...

Eli Lilly and Company (NYSE:LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription,... ByInvesting ...

Eli Lilly and Company LLY will report ... top-line growth is expected to have been driven by demand growth for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...